quizartinib
illumina,daiichi sankyo
['quantum-first', 'leukemia', 'quizartinib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'illumina']
congress | #ash22
mark levis presented a secondary analysis of the quantum-first trial, focusing on mrd status in pts achieving a crc. quizartinib treatment was associated with longer os versus placebo, regardless of mrd status. mrd negativity was also associated longer os. 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm